What Is Saxenda?

1. What Is Saxenda?

Saxenda is a Novo Nordisk prescription brand for liraglutide injection. The current DailyMed Saxenda label describes Saxenda as a glucagon-like peptide-1 (GLP-1) receptor agonist indicated with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in defined adult and pediatric populations.

That sentence packs several different facts into one summary. “Saxenda” is the brand. “Liraglutide” is the active ingredient. “GLP-1 receptor agonist” is the medication class. “Chronic weight management” is the primary condition it treats.

The official Saxenda patient site and NovoMedLink physician page use similar framing: Saxenda is liraglutide injection intended for weight management.

For broader category background, see What Is a GLP-1?. For the molecule behind Saxenda, see What Is Liraglutide?.

2. Why Is Liraglutide the Important Word?

Liraglutide is the active ingredient in Saxenda. This makes liraglutide the molecule-level answer, while Saxenda is the brand-level answer.

This distinction is useful because GLP-1 articles often mix several layers of naming. A person may see “Saxenda,” “liraglutide,” “GLP-1,” and “Novo Nordisk” in the same paragraph. While related, they are not interchangeable.

Here is how the naming stack breaks down:

Keeping these layers separate helps prevent confusion when discussing treatment options.

3. What Does the Current U.S. Label Say?

The current U.S. Saxenda label states it is used in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 12 years and older with a body weight greater than 60 kg and obesity, and in adults with overweight in the presence of at least one weight-related comorbid condition.

The adolescent wording is an important part of its official U.S. history. FDA announced on December 4, 2020, that Saxenda received a supplemental indication for chronic weight management among pediatric patients aged 12 and older who meet the label’s obesity and weight criteria. Saxenda has been approved since December 2014 for chronic weight management in adults with obesity, or adults with overweight and at least one weight-related condition.

The practical takeaway is that Saxenda is not only prescribed for adults; pediatric approval exists for adolescents who meet specific label criteria.

4. How Is Saxenda Different From Victoza?

Saxenda and Victoza both contain liraglutide, but they are used for different conditions. The current DailyMed Victoza label describes Victoza as a GLP-1 receptor agonist for type 2 diabetes glycemic control in adults and pediatric patients aged 10 years and older, plus cardiovascular risk reduction for adults with type 2 diabetes and established cardiovascular disease.

Saxenda is the liraglutide brand for chronic weight management, while Victoza is the liraglutide brand for type 2 diabetes. “Same active ingredient” is true, but it does not make them interchangeable.

For the molecule-first explanation, read What Is Liraglutide?. For the companion brand context, see What Is Victoza?.

5. How Is Saxenda Different From Wegovy and Ozempic?

Saxenda contains liraglutide. Wegovy and Ozempic contain semaglutide.

The indications differ too. Saxenda is a liraglutide brand centered on chronic weight management. Wegovy is a semaglutide brand centered on weight management and related labeled contexts. Ozempic is a semaglutide brand centered on type 2 diabetes. Semaglutide is the molecule behind Wegovy, Ozempic, and Rybelsus, not the molecule behind Saxenda.

Ultimately, while Saxenda and Wegovy are both well-known GLP-1 weight-management brand names, they utilize entirely different active ingredients.

6. How Is Saxenda Different From Zepbound and Mounjaro?

Saxenda also differs from tirzepatide brands. Zepbound and Mounjaro contain tirzepatide, not liraglutide. Current tirzepatide labels indicate they target both GIP and GLP-1 receptors, while Saxenda’s label identifies liraglutide solely as a GLP-1 receptor agonist.

Media and social posts often call all of these metabolic drugs “GLP-1s,” but that shorthand is incomplete for tirzepatide.

Here is how the prominent brands compare:

7. Why Saxenda Still Matters in GLP-1 Discussions

Saxenda remains relevant as it connects several eras of GLP-1 therapies. As a Novo Nordisk liraglutide brand, it predates the current wave of semaglutide and tirzepatide attention, and the FDA’s adolescent update gives it a documented place in chronic weight-management history.

Understanding Saxenda highlights how one active ingredient can appear under different brand names for entirely different conditions, and how common shorthand like “GLP-1” can sometimes obscure important differences between medications.

8. What Is Saxenda FAQ

• What is Saxenda in simple terms?

  Saxenda is a Novo Nordisk brand name for liraglutide injection. Current U.S. labeling describes Saxenda as a GLP-1 receptor agonist used in chronic weight management for defined adult and pediatric populations.

• Is Saxenda the same thing as liraglutide?

  No. Liraglutide is the active ingredient. Saxenda is a brand name for liraglutide injection. Victoza also contains liraglutide, but it is a different brand for type 2 diabetes.

• How is Saxenda different from Victoza?

  Saxenda and Victoza both contain liraglutide, but current U.S. labels point to different conditions. Saxenda is prescribed for chronic weight management, while Victoza is prescribed for type 2 diabetes and certain cardiovascular risk reduction in adults with type 2 diabetes.

• How is Saxenda different from Wegovy, Ozempic, or Zepbound?

  Saxenda contains liraglutide. Wegovy and Ozempic contain semaglutide, and Zepbound contains tirzepatide. Those names differ by active ingredient, brand, receptor targeting, and label indications.

9. Sources